Zai Lab Limited will announce its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). The company operates as a research-based, commercial-stage biopharmaceutical entity focused on oncology, immunology, neuroscience, and infectious disease.

Conference Call Details

Participants must register in advance to access the live webcast or dial-in for the conference call. A replay of the session will be available shortly after the conclusion of the call.

Access Information

The live webcast can be accessed through the company's investor relations website. Upon registering for the dial-in option, participants will receive a confirmation email containing the necessary call details. The replay will be accessible on the Zai Lab Limited website following the event.

Zai Lab Limited announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to zocilurtatug pelitecan (zoci) for the treatment of pulmonary neuroendocrine carcinomas (NECs). The designation is based on preliminary clinical data suggesting the drug offers a clinically relevant advantage over currently authorized therapies for patients with relapsed or refractory extensive-stage small cell lung cancer (SCLC).

The positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) recognizes the seriousness of neuroendocrine carcinomas and the critical need for new treatment options. Small cell lung cancer represents the most significant form of pulmonary NEC, accounting for approximately 15% of the 2.5 million global lung cancer diagnoses annually. This translates to an estimated 375,000 new cases each year, making it one of the most aggressive and lethal solid tumors.

The COMP specifically noted that zoci demonstrated durable responses in early clinical data, indicating a more favorable effect than existing therapies. Zai Lab's zoci is a potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC).

This European regulatory milestone closely follows recent actions by the U.S. Food and Drug Administration (FDA). The FDA previously granted Fast Track designation and Orphan Drug Designation to zoci for SCLC. Additionally, the FDA recently granted Fast Track designation to zoci for extrapulmonary neuroendocrine carcinomas (epNECs), with promising data presented at the AACR Annual Meeting in April 2026.

Regulatory Designations for Zoci